Antares Pharma to Host Third Quarter 2013 Operating and Financial Results Conference Call


Antares Pharma, Inc. (ATRS) today announced it will release its
third quarter 2013 financial results before the market opens on
Wednesday, November 6, 2013, and host a conference call shortly
thereafter at 8:30 a.m. ET (Eastern Time) to discuss the results. Paul
K. Wotton, Ph.D., President and Chief Executive Officer, and Robert F.
Apple, EVP, Chief Financial Officer, and President of the Parenteral
Products Division, will host the call.

Interested parties may participate in the conference call by dialing
1-800-762-8795 (US) or 1-480-629-9773 (international), 5-10 minutes
prior to the start of the call. A replay of the conference call will be
available approximately 2 hours after the call’s conclusion through
12:00 p.m. ET (Eastern Time) on November 20, 2013 by dialing
1-800-406-7325 (US) or 1-303-590-3030 (international), and entering the
access code 4647461. An audio web cast and archive of the conference
call will also be available under the investor relations section of the
Antares Web site at

About Antares Pharma

Antares Pharma focuses on self-administered parenteral pharmaceutical
products and topical gel-based medicines. The Company has received
marketing approval from the U.S. Food and Drug Administration for
OTREXUP™ (methotrexate) injection for the treatment of adults with
severe active rheumatoid arthritis, children with active polyarticular
juvenile idiopathic arthritis and adults with severe recalcitrant
psoriasis. Antares Pharma is also developing VIBEX® QS T for
testosterone replacement therapy. The Company’s technology platforms
include VIBEX® disposable Medi-Jet™, disposable multi-use pen
injectors and Vision™ reusable needle-free injectors marketed as Tjet®
and Zomajet® by Teva Pharmaceutical Industries, Ltd (Teva)
and Ferring Pharmaceuticals (Ferring), respectively. Antares Pharma has
a multi-product deal with Teva that includes Tev-Tropin®
[somatropin (rDNA origin) for injection] human growth hormone (hGH),
VIBEX® epinephrine and several other products. Antares
Pharma’s partnership with Ferring includes Zomacton® hGH
(somatropin) injection. In the U.S. Antares has received FDA approval
for Gelnique 3%™ (oxybutynin) gel, a treatment for overactive bladder
that is marketed by Actavis. Elestrin® (estradiol gel) is FDA
approved for the treatment of moderate-to-severe vasomotor symptoms
associated with menopause, and is marketed in the U.S. by Meda Pharma.
Antares Pharma has two facilities in the U.S. The Parenteral Products
Group located in Minneapolis, Minnesota directs the manufacturing and
marketing of the Company’s reusable needle-free injection devices and
related disposables, and develops its disposable pressure-assisted
Medi-Jet and pen injector systems. The Company’s corporate office and
Product Development and Commercial Groups are located in Ewing, New

Source Article from
Antares Pharma to Host Third Quarter 2013 Operating and Financial Results Conference Call
pharma – Yahoo News Search Results
pharma – Yahoo News Search Results


メールアドレスが公開されることはありません。 * が付いている欄は必須項目です

次のHTML タグと属性が使えます: <a href="" title=""> <abbr title=""> <acronym title=""> <b> <blockquote cite=""> <cite> <code> <del datetime=""> <em> <i> <q cite=""> <strike> <strong>